iBio Acquires RubrYc Therapeutics’ AI Drug Discovery Platform and Pipeline
iBio, Inc. (NYSEA:IBIO), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming® Manufacturing System, announced that it closed on the acquisition of substantially all of the assets of […]